2025 — HBOT efficacy review across rheumatic/immune diseases including FM
One-paragraph summary
Comprehensive review of HBOT efficacy across rheumatic and autoimmune diseases. Headline findings: HBOT efficacy rate of 87.5-100% in treating rheumatic and autoimmune disease complications including skin ulcers; pain relief rate 87.5-100% in fibromyalgia syndrome patients across cited studies. Mechanism framing: hypoxia plays a role in rheumatic/autoimmune disease pathogenesis; HBOT increases dissolved plasma oxygen and arterial oxygen partial pressure; reduces hypoxia-induced pathological cellular stress and cell death. Also favorable effects in sensorineural hearing loss, autoimmune skin conditions, and other extra-articular manifestations. For the project, this is the headline-efficacy citation for HBOT in FM (87.5-100% pain relief) that justifies promoting HBOT to cure-path arm consideration in a future white paper version.
Claims as triples
hyperbaric_oxygen_therapy — modulates → widespread_pain[evidence: review of 87.5-100% pain-relief rate in FM cohorts; confidence: emerging]hyperbaric_oxygen_therapy — modulates → fm_autoimmune[evidence: review of efficacy across rheumatic/autoimmune diseases including FM; confidence: emerging]
Triangulation notes
- Promotes HBOT to candidate cure-path arm consideration for a future white-paper version. Currently §12 has 9 arms; HBOT becomes a candidate §12.X to consider against the cure-path-arm decision protocol (would need to be added with a pre-specified retirement trigger per the new protocol).
- Compatible with Hypothesis 1's mitochondrial-quality-control framework (oxygen-tension-driven mitochondrial respiration support).
- Pairs with the 2025 HBOT long-COVID RCT (n=101) as the project's HBOT evidence base.
- Discovered via Probe 4; scored ingestion-worthy; promoted in Recommendation 3.